New German reimbursement system stutters again
This article was originally published in Clinica
A disagreement on key issues is threatening to hold up the introduction of Germany's new hospital reimbursement system, the diagnosis related groups (DRGs). Despite the eagerness of the ruling Social Democratic Party (SPD) and Green Party coalition to push a law enacting the DRGs through the Upper House (Bundesrat), the opposition Christian Democrat and Socialist Union (CDU/CSU) parties want the law referred to the parliamentary arbitration committee, to resolve two key problems.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.